Yutaka Okayama

Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings

Takanori Ikeda, Satoshi Ogawa, Takanari Kitazono et al. · Journal of Thrombosis and Thrombolysis · 2019 · 52 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study

Shuichi Kaneko, Kenji Ikeda, Yasushi Matsuzaki et al. · Journal of Gastroenterology · 2016 · 35 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance

Hideyuki Akaza, Mototsugu Oya, Masafumi Iijima et al. · Japanese Journal of Clinical Oncology · 2015 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS)

Takanori Ikeda, Satoshi Ogawa, Takanari Kitazono et al. · Journal of Cardiology · 2019 · 30 citations

Pharmacy, Cardiology, Pharmacotherapy +10

Design and baseline characteristics of the Xarelto Post‐Authorization Safety &amp; Effectiveness Study in Japanese Patients with Atrial Fibrillation (<scp>XAPASS</scp>)

Satoshi Ogawa, Kazuo Minematsu, Takanori Ikeda et al. · Journal of Arrhythmia · 2018 · 16 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14